Prevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians

Abstract

Abstract Increased COVID‐19 vaccine hesitancy presents a major hurdle in global efforts to contain the COVID‐19 pandemic. This study was designed to estimate the prevalence of adverse events after the first dose of the Covishield (AstraZeneca) vaccine among physicians in Bangladesh. A cross‐sectional study was conducted using an online questionnaire for physicians (n = 916) in Bangladesh. Physicians who received at least one dose of the COVID‐19 vaccine were included. The study was carried out from April 12 to May 31, 2021. More than 58% of respondents (n = 533) reported one or more adverse events. Soreness of the injected arm (71.9%), tiredness (56.1%), fever (54.4%), soreness of muscles (48.4%), headache (41.5%) and sleeping more than usual (26.8%) were the most commonly reported adverse events. Most vaccine‐related reactogenicities were reported by the younger cohorts (<45 years). The majority of respondents reported severity of reactogenicity as “mild,” experienced on the day of vaccination, and lasting for 1–3 days. The most common reactogenicity was pain at the injection site; the second most common was tiredness. Almost half (49.2%) of the physicians took acetaminophen (paracetamol) to minimize the effects of vaccine reactogenicity. Multivariate logistic regression analyses showed that physicians with diabetes and hypertension (OR = 2.729 95% CI: 1.282–5.089) and asthma with other comorbidities (OR = 1.885 95% CI: 1.001–3.551) had a significantly higher risk of vaccine‐related reactogenicities than physicians without comorbidities. Further safety studies with larger cohorts are required to monitor vaccine safety and provide assurance to potential vaccine recipients.

Keywords

• AstraZeneca vaccine
• Bangladesh
• COVID‐19
• physicians
• reactogenicity